A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl

Journal of Nephrology

Volumn 27, Issue 4, 2014, Pages 457-460

  Besbas, Nesrin ^a   Gulhan, Bora ^a   Gucer, Safak ^a   Korkmaz, Emine ^a   Ozaltin, Fatih ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

C3 glomerulopathy; CFHR5 mutation; CFHR5 related nephropathy; Eculizumab; Hypocomplementemia; Nephrotic syndrome

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H RELATED PROTEIN 5; ECULIZUMAB; ENALAPRIL; IMMUNOGLOBULIN M; LOSARTAN; PREDNISONE; STEROID; UNCLASSIFIED DRUG; COMPLEMENT; FHR5 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; C3 GLOMERULONEPHRITIS; CASE REPORT; COMPLEMENT FACTOR H RELATED PROTEIN 5 GENE; ELECTRON MICROSCOPY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC SCREENING; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; KIDNEY BIOPSY; KIDNEY FIBROSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MICROSCOPY; PERIORBITAL EDEMA; PROTEINURIA; TURK (PEOPLE); URINALYSIS; GENETICS; HETEROZYGOTE; METABOLISM; MUTATION; PATHOLOGY; TREATMENT FAILURE;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C3; COMPLEMENT SYSTEM PROTEINS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HETEROZYGOTE; HUMANS; MUTATION; TREATMENT FAILURE;

EID: 84904461594     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-013-0008-1     Document Type: Article

References (15)

1. Braun MC, Licht C, Strife CF (2009) Membranoproliferative glomerulonephritis. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds) Pediatric nephrology, 6th edn. Springer, Berlin, pp 783-797.
2. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC (2010) C3 glomerulopathy: a new classification. Nat Rev Nephrol 6(8): 494-499.
3. Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis-a new look at an old entity. N Engl J Med 366(12): 1119-1131.
4. Servais A, Frémeaux-Bacchi V, Lequintrec M et al (2007) Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44(3): 193-199.
5. Sethi S, Fervenza FC, Zhang Y et al (2011) Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 6(5): 1009-1017.
6. Murphy B, Georgiou T, Machet D, Hill P, McRae J (2002) Factor H-related protein-5: a novel component of human glomerular immune deposits. Am J Kidney Dis 39(1): 24-27.
7. Gale DP, de Jorge EG, Cook HT et al (2010) Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376(9743): 794-801.
8. Athanasiou Y, Voskarides K, Gale DP et al (2011) Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 6(6): 1436-1446.
9. Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and a server for predicting damaging missense mutations. Nat Methods 7(4): 248-249.
10. Wada T, Nangaku M (2013) Novel roles of complement in renal diseases and their therapeutic consequences. Kidney Int. doi: 10. 1038/ki. 2013. 134.
11. Barbour TD, Pickering MC, Cook HT (2013) Recent insights into C3 glomerulopathy. Nephrol Dial Transpl. doi: 10. 1093/ndt/gfs430.
12. Servais A, Noël LH, Frémeaux-Bacchi V, Lesavre P (2013) C3 glomerulopathy. Contrib Nephrol 181: 185-193.
13. Abrera-Abeleda MA, Nishimura C, Smith JL et al (2006) Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 43(7): 582-589.
14. Servais A, Noël LH, Roumenina LT et al (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82(4): 454-464.
15. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V (2012) French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8(11): 643-657.